EMT ‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Molecular Oncology · 2025-11 · 19 (11) · 3360-3375
DOI: 10.1002/1878-0261.70066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 18.06.2025. Verfasst von Nele Vandenbussche und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Medical Genetics, Ghent University Hospital, Belgium. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Epithelial-Mesenchymal Transition, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bijzonder Onderzoeksfonds UGent.
Abstract (Originalsprache)
Pancreatic cancer has a 5‐year survival rate of 12%, highlighting the need for reliable biomarkers for early detection and disease monitoring. Circulating tumor cells (CTCs) have emerged as a promising biomarker, yet their detection remains challenging. This study evaluates the Parsortix® system, a microfluidic device that enriches CTCs based on size and deformability, using pancreatic cancer cell lines. As increasing evidence indicates that during epithelial‐to‐mesenchymal transition (EMT) a cell's deformability increases, we evaluated possible biases by the device. The EMT stage of three pancreatic cancer cell lines, CAPAN‐1, MIA PaCa‐2, and PANC‐1, was assessed to classify them as epithelial, mesenchymal‐like, and hybrid, respectively. Spike‐in experiments showed that epithelial and hybrid phenotypes were more efficiently captured (62.6 ± 18.5% and 65.4 ± 11.1%) than mesenchymal‐like cancer cells (32.8 ± 10.2%). These results were confirmed using an EMT‐inducible breast cancer cell line. Lower recovery rates were found for the cells in a mesenchymal‐like state (31.5 ± 6.4%) than those in an epithelial state (47.56 ± 7.2%). In conclusion, the Parsortix® device may underestimate the number of mesenchymal CTCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Medical Genetics, Ghent University Hospital, Belgium.
- Department of Biomolecular Medicine, Ghent University, Belgium.
- Cancer Research Institute Ghent (CRIG), Belgium.
- VIB Center for Medical Biotechnology, Ghent, Belgium.
- Molecular and Cellular Oncology Lab, Inflammation Research Center (IRC), Ghent, Belgium.
- Department of Biomedical Molecular Biology, Ghent University, Belgium.
ORCID-Profile: Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B M Claes
Förderung
- Bijzonder Onderzoeksfonds UGent
Zitieren
APA
Vandenbussche, N., Imschoot, R., Lintermans, B., Denolf, L., Taminau, J., Fieuws, C., Berx, G., Gevaert, K., & Claes, K. B. M. (2025). EMT ‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines. Molecular Oncology, 19(11), 3360-3375. https://doi.org/10.1002/1878-0261.70066
Vancouver
Vandenbussche N, Imschoot R, Lintermans B, Denolf L, Taminau J, Fieuws C, et al. EMT ‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines. Molecular Oncology. 2025;19(11):3360-3375. doi:10.1002/1878-0261.70066
BibTeX
@article{Vandenbussche2025,
author = {Vandenbussche, Nele and Imschoot, Renske and Lintermans, Béatrice and Denolf, Lode and Taminau, Joachim and Fieuws, Charlotte and Berx, Geert and Gevaert, Kris and Claes, Kathleen B M},
title = {EMT ‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {11},
pages = {3360--3375},
doi = {10.1002/1878-0261.70066}
}
EUVIMED